Prelude Therapeutics PRLD
NASDAQ PRLD
$5.46 +0.21 (+4.00%)
As of: Sep 4, 2026 · 3:59 PM EDT

Prelude Therapeutics (PRLD) Operating Income Growth (3y) (2022 - 2026)

Analysis

Prelude Therapeutics (PRLD) Operating Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 8.36%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 89.72%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -18.82%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 81.27%
10 Prelude Therapeutics 539.17 Mn 258.54 Mn - 21.87%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 21.87%
Mar 31, 2026 21.33%
Dec 31, 2025 19.60%
Sep 30, 2025 12.43%
Jun 30, 2025 -3.00%
Mar 31, 2025 -4.54%
Dec 31, 2024 -0.82%
Sep 30, 2024 -3.69%
Jun 30, 2024 -10.00%
Mar 31, 2024 -16.06%
Dec 31, 2023 -24.34%
Sep 30, 2023 -22.54%
Jun 30, 2023 -41.50%
Mar 31, 2023 -44.07%
Dec 31, 2022 -48.99%
Sep 30, 2022 -64.07%